Novartis Culls Fevipiprant After LackLUSTER Data
Asthma Pill Fails Second Set Of Studies
Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.
You may also be interested in...
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.